Filing Flows › Myriad Genetics (MYGN) › Q2 2025
Myriad Genetics (MYGN) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Myriad Genetics (MYGN) reported revenue of $213M for the second quarter 2025 (Q2 2025), +0.8% from a year earlier and +9% from the quarter before. Operating margin was -154.5%, net loss $330M (155.1% of revenue).
Myriad Genetics, Q2 2025: revenue $213M (+0.8% year over year), operating margin -154.5%, net loss $330M, operating cash flow −$13.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $213M | +9% | +0.8% |
| Operating profit | −$329M | — | — |
| Net earnings | −$330M | — | — |
| Operating cash flow | −$13.6M | — | — |
What changed
Revenue was $213.1M in Q2 2025, up 1% year over year and up 9% from the previous quarter. Hereditary Cancer was the largest line at 45% of revenue. Hereditary Cancer added $4.8M year over year (up 5%), 300% of the total change. Pharmacogenomics declined 12%.
Gross margin was 71.2%, up 1.7 points from a year earlier. Operating costs exceeded revenue by $329.2M, an operating margin of -154.5%. Operating expenses grew 162% against revenue growth of 1%. The fastest-growing cost line was Other operating costs (+2630%). The quarter ended with a net loss of $330.5M, wider than the previous quarter's $100K loss.
Operating cash flow was −$13.6M. Non-cash charges added back $14.1M of depreciation and amortization and $10.7M of share-based compensation. Working capital and other items added $292.1M. Capital expenditures of $2.8M exceeded it, leaving free cash flow of −$16.4M.
Questions
What was Myriad Genetics' revenue in the second quarter 2025?
Myriad Genetics (MYGN) reported revenue of $213M for the second quarter 2025 (Q2 2025), +0.8% from a year earlier and +9% from the quarter before.
Was Myriad Genetics profitable in the second quarter 2025?
Operating loss was $329M (-154.5% of revenue) and net loss $330M.
Source: Myriad Genetics 10-Q on SEC EDGAR.